TempraMed Secures South Korean Patent for VIVI Box Temperature-Controlled Medication Storage System
Key Insights
TempraMed Technologies (search) has been granted a South Korean patent for its VIVI Box (search) system, a consumer-focused medical storage device that maintains temperature-sensitive medications at 8°C for up to 24 hours without external power.
The patented system addresses the growing need for safe storage of high-value biologics (search), GLP-1 therapies (search), insulin, and specialty medications by preventing freezing and providing continuous temperature protection during power outages or refrigerator fluctuations.
The patent expands TempraMed's intellectual property portfolio and enhances commercialization opportunities in Asia's premium refrigeration market, supporting the company's strategy to evolve beyond single-injection protection into multi-dose medication storage solutions.
TempraMed Technologies (search) Ltd. has secured a significant patent grant in South Korea for its VIVI Box (search)™ medical storage system, marking a crucial advancement in the company's mission to transform temperature-sensitive medication management. The patent, issued under Korean Patent Application No. 10-2021-7011422, protects the company's proprietary thermal-insulation system and smart-monitoring architecture designed for domestic refrigerator use.
Revolutionary Storage Technology for Critical Medications
The VIVI Box (search) represents a breakthrough in consumer-focused medical storage, engineered to maintain temperature-sensitive medications within a secure 8°C environment for up to 24 hours without external power. The system addresses critical gaps in medication storage by preventing freezing, stabilizing temperatures, and providing uninterrupted protection during routine use, travel, transportation, or unexpected power outages.
The patented technology specifically targets fast-growing medication categories including insulin, GLP-1 therapies (search), biologics (search), and other specialty drugs. These medications require precise temperature control to maintain their therapeutic efficacy, making the VIVI Box (search)'s capabilities particularly valuable for patients managing chronic conditions requiring self-injectable treatments.
Advanced Features and Smart Integration
The South Korean patent encompasses several key technological capabilities that distinguish VIVI Box (search) from conventional storage solutions. The system provides continuous temperature protection during power interruptions or refrigerator temperature fluctuations, ensuring medication integrity regardless of external circumstances. Additionally, it functions as a portable, all-day travel solution for users requiring secure on-the-go cold storage.
The device incorporates smart content tracking with cloud-based data integration to support medication adherence and remote monitoring. These capabilities position VIVI Box (search) as a differentiated platform at the intersection of home health, smart refrigeration, and the consumer IoT medical-device ecosystem.
Strategic Expansion and Market Positioning
"Being granted this additional patent in South Korea marks an important milestone in our mission to redefine temperature stability and management for medications worldwide," said Ron Nagar, CEO of TempraMed. "VIVI Box (search) represents the next major step in our strategy to move beyond single-device protection and deliver scalable, multi-medication storage solutions for patients and healthcare systems."
The patent grant enhances TempraMed's commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia's premium refrigeration market. This expansion aligns with the company's broader strategy to adapt its core technology to a wider range of drug categories, from chronic self-injectables to complex biologics (search).
Growing Market Demand and Global Reach
Nagar emphasized the increasing market demand for temperature-stable storage solutions: "As more high-value biologics (search), peptides, GLP-1 therapies (search), and specialty medications enter the market, the need for safe, compliant, and temperature-stable storage continues to grow dramatically. Combined with our expanding patent portfolio, deep distribution partnerships, and commitment to engineering excellence, TempraMed is exceptionally well-positioned to lead the next chapter of innovation."
The South Korean patent follows recent milestones including exclusive distribution agreements across Israel, Turkey, and major European regions with partners such as Guri A.A.O (search), Dolfin Sağlık (search), and Salomo Executive (search). These partnerships expand TempraMed's reach across retail pharmacy chains, HMOs, and healthcare networks.
Technology Platform and Future Development
TempraMed's technology platform builds on the company's proven product line including VIVI Cap (search) and VIVI Epi (search), utilizing patented, FDA-registered, space-grade thermal insulation devices that operate continuously without batteries or external power. The VIVI Box (search) invention advances the company's strategy to evolve beyond single-injection protection into multi-dose, multi-format medication-storage systems, representing core components of TempraMed's long-term commercialization plan.
The company's mission focuses on safeguarding the effectiveness of life-saving medications while reducing medication waste and redefining storage standards globally. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed continues to advance the future of medication protection and adherence through innovative temperature-controlled storage solutions.